Key points are not available for this paper at this time.
Chronic diseases are often characterized through the repeated occurrence of unfavorable events. In chronic heart failure (CHF), recurrent hospitalizations characterize disease burden but the risk of death is not negligible. This leads to two main challenges. First, the definition of a clinically interpretable treatment effect measure (estimand) needs careful attention. Second, finding suitable analysis methods (estimators) that target the estimand of interest is difficult. In this article,we study the two estimands using the while-alive strategy described by Schmidli et al. For realistic CHF populations based on joint frailty model assumptions, we calculate the estimand values analytically and discuss their clinical interpretability. We also show that quasi-Poisson regression leads to an asymptotically unbiased estimator for the two estimands using the while-alive strategy, and that Lin-Wei-Yang-Ying is asymptotically unbiased under constant event rate conditional on being alive, by both analytic derivation and numerical simulations. We also investigate these estimators, together with the method-of-moments-estimator, in two CHF clinical trials. The findings in this article support the claim that treatment effect measures can be defined based on recurrent event endpoints that are clinically interpretable and statistically estimable.
Wei et al. (Thu,) studied this question.